UroGen Pharma (URGN) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free URGN Stock Alerts $13.10 -0.12 (-0.91%) (As of 11:19 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | americanbankingnews.comUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q2 2024 Earnings of ($0.83) Per Share, HC Wainwright ForecastsMay 15, 2024 | americanbankingnews.comUroGen Pharma's (URGN) Buy Rating Reiterated at HC WainwrightMay 15, 2024 | americanbankingnews.comOppenheimer Lowers UroGen Pharma (NASDAQ:URGN) Price Target to $32.00May 14, 2024 | markets.businessinsider.comUroGen Pharma Holds Steady Amidst Financial Underperformance and Anticipated Study ResultsMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma as UGN-102 Progresses Towards FDA Approval and Market SuccessMay 14, 2024 | msn.comUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) PT Lowered to $32.00 at OppenheimerOppenheimer lowered their price target on UroGen Pharma from $34.00 to $32.00 and set an "outperform" rating on the stock in a report on Tuesday.May 14, 2024 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for UroGen Pharma (NASDAQ:URGN)HC Wainwright restated a "buy" rating and set a $54.00 price objective on shares of UroGen Pharma in a research report on Tuesday.May 14, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 14, 2024 | finance.yahoo.comUroGen Pharma First Quarter 2024 Earnings: Misses ExpectationsMay 13, 2024 | investorplace.comURGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024May 13, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above ExpectationsMay 13, 2024 | marketbeat.comTrading was temporarily halted for "URGN" at 09:05 AM with a stated reason of "LULD pause." Trading set to resume at 09:05 AM. May 13, 2024 | businesswire.comUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business HighlightsMay 12, 2024 | finance.yahoo.comShareholders in UroGen Pharma (NASDAQ:URGN) have lost 67%, as stock drops 11% this past weekMay 11, 2024 | americanbankingnews.comUroGen Pharma (URGN) Set to Announce Earnings on MondayMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma on Strong Clinical Data and Market PotentialMay 5, 2024 | businesswire.comNew Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction TherapyMay 4, 2024 | businesswire.comUroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024May 4, 2024 | businesswire.comNew Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal TrialMay 3, 2024 | businesswire.comUroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024April 20, 2024 | marketbeat.com125,226 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Cerity Partners LLCCerity Partners LLC bought a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 125,226 shares of the company's stock, valued atApril 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Urogen Pharma Amid Promising Clinical Data and Strategic Conference PresentationsApril 18, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $54.00 price target on shares of UroGen Pharma in a research report on Thursday.April 17, 2024 | businesswire.comUroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial CancersApril 16, 2024 | investing.comUroGen's UGN-103 advances to Phase 3 for bladder cancerApril 15, 2024 | businesswire.comUroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerApril 14, 2024 | finance.yahoo.comUroGen Pharma Ltd.'s (NASDAQ:URGN) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekApril 4, 2024 | markets.businessinsider.comUrogen Pharma’s Strategic Defense and Pipeline Progress Bolster Buy RatingApril 4, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $54.00 price target on shares of UroGen Pharma in a research note on Thursday.March 22, 2024 | insidertrades.comUroGen Pharma Ltd. (NASDAQ:URGN) Insider Sells $168,600.00 in StockMarch 20, 2024 | marketbeat.comMark Schoenberg Sells 12,000 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) StockUroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 12,000 shares of UroGen Pharma stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.05, for a total transaction of $168,600.00. Following the completion of the sale, the insider now owns 139,437 shares of the company's stock, valued at $1,959,089.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.March 19, 2024 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) to Post Q1 2025 Earnings of ($0.73) Per Share, HC Wainwright ForecastsUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of UroGen Pharma in a research report issued to clients and investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju forecasts thatMarch 18, 2024 | seekingalpha.comUroGen: All Eyes On UGN-102March 18, 2024 | marketbeat.comOppenheimer Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $34.00Oppenheimer lowered their price objective on UroGen Pharma from $35.00 to $34.00 and set an "outperform" rating for the company in a research report on Friday.March 17, 2024 | finance.yahoo.comUroGen Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineMarch 15, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Urogen Pharma (URGN) and Cullinan Management (CGEM)March 14, 2024 | finanznachrichten.deUroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102March 14, 2024 | finance.yahoo.comUroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial ChallengesMarch 14, 2024 | investorplace.comURGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023March 14, 2024 | finance.yahoo.comUroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102March 13, 2024 | markets.businessinsider.comUroGen Pharma earnings preview: what to expectMarch 9, 2024 | marketbeat.comSchonfeld Strategic Advisors LLC Purchases Shares of 130,200 UroGen Pharma Ltd. (NASDAQ:URGN)Schonfeld Strategic Advisors LLC purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 130,200 shares of the company's stock, valued at approxMarch 8, 2024 | businesswire.comUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 4, 2024 | finance.yahoo.comUroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024March 1, 2024 | stocknews.com3 Biotech Stocks Climbing the Ranks to WatchMarch 1, 2024 | msn.comUroGen falls as Teva seeks FDA nod for Jelmyto genericFebruary 26, 2024 | businesswire.comUroGen Pharma to Present at TD Cowen 44th Annual Health Care ConferenceFebruary 19, 2024 | finance.yahoo.comURGN Mar 2024 22.500 call Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. URGN Media Mentions By Week URGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼-0.060.42▲Average Medical News Sentiment URGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼202▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vanda Pharmaceuticals News Today XOMA News Today 23andMe News Today Nature's Sunshine Products News Today Ventyx Biosciences News Today CorMedix News Today Rani Therapeutics News Today Aquestive Therapeutics News Today Mersana Therapeutics News Today Atai Life Sciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldUrgent Nvidia WarningAltimetryDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
